**International Flavors & Fragrances Inc.**
**GAAP to Non-GAAP Reconciliation**
**(Unaudited)**

The following information and schedules provide reconciliation information between reported GAAP amounts and non-GAAP certain adjusted amounts. This information and schedules are not intended as, and should not be viewed as, a substitute for reported GAAP amounts or financial statements of the Company prepared and presented in accordance with GAAP.

For the three months ended June 30, 2026 and 2025, there was no difference between Reported (GAAP) and Adjusted (Non-GAAP) gross profit.

**Reconciliation of Selling and Administrative Expenses[1]**

| | Second Quarter | |
|---|---|---|
| *(DOLLARS IN MILLIONS)* | **2026** | **2025** |
| Reported (GAAP) | $ 437 | $ 409 |
| Divestiture Costs (b) | (10) | (26) |
| Strategic Initiatives Costs (e) | (9) | (6) |
| Regulatory Costs (f) | (71) | (53) |
| Entity Realignment Costs (h) | (1) | (2) |
| Adjusted (Non-GAAP) | $ 346 | $ 322 |

**International Flavors & Fragrances Inc.**
**GAAP to Non-GAAP Reconciliation**
**(Unaudited)**

The following information and schedules provide reconciliation information between reported GAAP amounts and non-GAAP certain adjusted amounts. This information and schedules are not intended as, and should not be viewed as, a substitute for reported GAAP amounts or financial statements of the Company prepared and presented in accordance with GAAP.

**Reconciliation of Net Income (Loss) and EPS from Continuing Operations[1]**

| | Second Quarter | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | 2026 | | | | 2025 | | | |
| *(DOLLARS IN MILLIONS EXCEPT PER SHARE AMOUNTS)* | Income before taxes | (Benefit) Provision for income taxes (i) | Net income attributable to IFF | Diluted EPS | Income before taxes | (Benefit) Provision for income taxes (i) | Net income attributable to IFF | Diluted EPS |
| Reported (GAAP) | $ 64 | $ 31 | $ 33 | $ 0.13 | $ 438 | $ (112) | $ 550 | $ 2.14 |
| Restructuring and Other Charges (a) | 6 | 1 | 5 | 0.02 | 20 | 5 | 15 | 0.06 |
| Divestiture Costs (b) | 10 | 1 | 9 | 0.04 | 26 | 22 | 4 | 0.02 |
| Losses on Business Disposals (c) | 1 | — | 1 | — | 111 | (137) | 248 | 0.97 |
| Losses on Assets Classified as Held for Sale (d) | 27 | 4 | 23 | 0.09 | — | — | — | — |
| Strategic Initiative Costs (e) | 9 | 2 | 7 | 0.02 | 6 | 1 | 5 | 0.02 |
| Regulatory Costs (f) | 71 | — | 71 | 0.27 | 53 | 12 | 41 | 0.16 |
| Gain on debt extinguishment (g) | — | — | — | — | (488) | (116) | (372) | (1.45) |
| Entity Realignment Costs (h) | 1 | — | 1 | — | 4 | 361 | (357) | (1.40) |
| Other (i) | (1) | — | (1) | — | 2 | — | 2 | — |
| Adjusted (Non-GAAP) | $ 188 | $ 39 | $ 149 | $ 0.57 | $ 172 | $ 36 | $ 136 | $ 0.52 |

**Reconciliation of Adjusted (Non-GAAP) EPS ex. Amortization[1]**

| | Second Quarter | |
|---|---|---|
| *(DOLLARS AND SHARE AMOUNTS IN MILLIONS)* | 2026 | 2025 |
| **Numerator** | | |
| Adjusted (Non-GAAP) Net Income | $ 149 | $ 136 |
| Amortization of Acquisition related Intangible Assets | 82 | 82 |
| Tax impact on Amortization of Acquisition related Intangible Assets (j) | 20 | 20 |
| Amortization of Acquisition related Intangible Assets, net of tax (k) | 62 | 62 |
| Adjusted (Non-GAAP) Net Income ex. Amortization | $ 211 | $ 198 |
| **Denominator** | | |
| Weighted average shares assuming dilution (diluted) | 257 | 257 |
| **Adjusted (Non-GAAP) EPS ex. Amortization** | $ 0.82 | $ 0.77 |

(a) For 2026 and 2025, represents costs related to severance as part of the IFF Productivity Program.

(b) For 2026 and 2025, primarily represents costs related to the Company's completed divestitures. These costs primarily consisted of external consulting fees, professional and legal fees and salaries of individuals who are fully dedicated to such efforts.

(c) For 2026, primarily represents losses recognized as part of final settlement adjustments related to the divestiture of the Nitrocellulose business in 2025. For 2025, primarily represents losses recognized as part of the sale of the Pharma Solutions disposal group, offset in part by gains recognized as part of the sale of the Nitrocellulose business.

(d) For 2026, represents the losses recognized on assets classified as held for sale of the CitraSource business.

(e) Represents costs related to the Company's strategic assessment and business portfolio optimization efforts and reorganizing the Global Business Services (GBS) Centers. In 2026, the GBS reorganization has been expanded to include additional functions such as customer service, supply chain and logistics in addition to human resources, accounting and finance, as well as additional efforts to automate processes and expand the use of artificial intelligence (AI) for these functions. These costs primarily consisted of external consulting fees and salaries of individuals who are fully dedicated to such efforts. Costs to develop software and AI are only included to the extent that they do not qualify for capitalization.

(f) For 2026 and 2025, represents costs primarily related to legal fees incurred and provisions recognized for the ongoing investigations of the fragrance businesses.

(g) For 2025, represents the gain recognized on the extinguishment of debt in connection with the completion of tender offers.

(h) For 2025, the Company implemented a phased restructuring initiative aimed at optimizing its legal entity framework. A one-time tax benefit was achieved as part of this restructuring which is partially offset by the execution costs to implement.

(i) For 2025, represents the net impact of costs related to severance, including accelerated stock compensation expense, for certain executives who have separated from the Company.

(j) The income tax effects of non-GAAP adjustments are calculated based on the applicable statutory tax rate for the relevant jurisdiction, except for those items which are non-taxable or subject to valuation allowances for which the tax expense (benefit) was calculated at 0%. The tax benefit for amortization is calculated in a similar manner as the tax effects of the non-GAAP adjustments.

(k) Represents all amortization of intangible assets acquired in connection with acquisitions, net of tax.

**International Flavors & Fragrances Inc.**
**GAAP to Non-GAAP Reconciliation**
**(Unaudited)**

The following information and schedules provide reconciliation information between reported GAAP amounts and non-GAAP certain adjusted amounts. This information and schedules are not intended as, and should not be viewed as, a substitute for reported GAAP amounts or financial statements of the Company prepared and presented in accordance with GAAP.

For the six months ended June 30, 2026 and 2025, there was no difference between Reported (GAAP) and Adjusted (Non-GAAP) gross profit.

**Reconciliation of Selling and Administrative Expenses[1]**

| | Second Quarter Year-to-Date | |
|---|---|---|
| *(DOLLARS IN MILLIONS)* | **2026** | **2025** |
| Reported (GAAP) | $ 771 | $ 799 |
| Divestiture Costs (c) | (15) | (77) |
| Strategic Initiatives Costs (f) | (18) | (14) |
| Regulatory Costs (g) | (81) | (64) |
| Entity Realignment Costs (i) | (2) | (4) |
| Other (j) | 1 | (5) |
| Adjusted (Non-GAAP) | $ 656 | $ 635 |

**International Flavors & Fragrances Inc.**
**GAAP to Non-GAAP Reconciliation**
**(Unaudited)**

The following information and schedules provide reconciliation information between reported GAAP amounts and non-GAAP certain adjusted amounts. This information and schedules are not intended as, and should not be viewed as, a substitute for reported GAAP amounts or financial statements of the Company prepared and presented in accordance with GAAP.

**Reconciliation of Net Income (Loss) and EPS from Continuing Operations[1]**

| | Second Quarter Year-to-Date | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | 2026 | | | | 2025 | | | |
| *(DOLLARS IN MILLIONS EXCEPT PER SHARE AMOUNTS)* | Income before taxes | Provision (Benefit) for income taxes (k) | Net income attributable to IFF (l) | Diluted EPS | Income before taxes | Provision (Benefit) for income taxes (k) | Net income attributable to IFF (l) | Diluted EPS |
| Reported (GAAP) | $ 260 | $ 72 | $ 187 | $ 0.73 | $ 526 | $ (92) | $ 617 | $ 2.40 |
| Restructuring and Other Charges (a) | 10 | 3 | 7 | 0.03 | 35 | 8 | 27 | 0.11 |
| Impairment of Goodwill (b) | — | — | — | — | 34 | — | 34 | 0.13 |
| Divestiture Costs (c) | 15 | 2 | 13 | 0.06 | 77 | 34 | 43 | 0.17 |
| Losses on Business Disposals (d) | 1 | — | 1 | — | 111 | (137) | 248 | 0.97 |
| Losses on Assets Classified as Held for Sale (e) | 27 | 4 | 23 | 0.09 | — | — | — | — |
| Strategic Initiative Costs (f) | 18 | 4 | 14 | 0.05 | 14 | 3 | 11 | 0.04 |
| Regulatory Costs (g) | 81 | 3 | 78 | 0.30 | 64 | 15 | 49 | 0.19 |
| Gain on debt extinguishment (h) | — | — | — | — | (488) | (116) | (372) | (1.45) |
| Entity Realignment Costs (i) | 2 | 1 | 1 | — | 5 | 361 | (356) | (1.40) |
| Other (j) | (2) | — | (2) | — | 6 | — | 6 | 0.02 |
| Adjusted (Non-GAAP) | $ 412 | $ 89 | $ 322 | $ 1.26 | $ 384 | $ 76 | $ 307 | $ 1.18 |

**Reconciliation of Adjusted (Non-GAAP) EPS ex. Amortization[1]**

| | Second Quarter Year-to-Date | |
|---|---|---|
| *(DOLLARS AND SHARE AMOUNTS IN MILLIONS)* | 2026 | 2025 |
| **Numerator** | | |
| Adjusted (Non-GAAP) Net Income | $ 322 | $ 307 |
| Amortization of Acquisition related Intangible Assets | 166 | 162 |
| Tax impact on Amortization of Acquisition related Intangible Assets (k) | 41 | 40 |
| Amortization of Acquisition related Intangible Assets, net of tax (m) | 125 | 122 |
| Adjusted (Non-GAAP) Net Income ex. Amortization | $ 447 | $ 429 |
| **Denominator** | | |
| Weighted average shares assuming dilution (diluted) | 257 | 257 |
| **Adjusted (Non-GAAP) EPS ex. Amortization** | $ 1.74 | $ 1.67 |

(a) For 2026 and 2025, represents costs related to severance as part of the IFF Productivity Program.

(b) For 2025, represents the impairment of goodwill related to the Food Ingredients reporting unit that is not included in the Food Ingredients or SCL disposal groups.

(c) For 2026 and 2025, primarily represents costs related to the Company's completed and anticipated divestitures. These costs primarily consisted of external consulting fees, professional and legal fees and salaries of individuals who are fully dedicated to such efforts.

(d) For 2026, primarily represents losses recognized as part of final settlement adjustments related to the divestiture of the Nitrocellulose business in 2025. For 2025, primarily represents losses recognized as part of the sale of the Pharma Solutions disposal group, offset in part by gains recognized as part of the sale of the Nitrocellulose business.

(e) For 2026, represents the losses recognized on assets classified as held for sale of the CitraSource business.

(f) Represents costs related to the Company's strategic assessment and business portfolio optimization efforts and reorganizing the Global Business Services (GBS) Centers. In 2026, the GBS reorganization has been expanded to include additional functions such as customer service, supply chain and logistics in addition to human resources, accounting and finance, as well as additional efforts to automate processes and expand the use of artificial intelligence (AI) for these functions. These costs primarily consisted of external consulting fees and salaries of individuals who are fully dedicated to such efforts. Costs to develop software and AI are only included to the extent that they do not qualify for capitalization.

(g) For 2026 and 2025, represents costs primarily related to legal fees incurred and provisions recognized for the ongoing investigations of the fragrance businesses.

(h) For 2025, represents the gain recognized on the extinguishment of debt in connection with the completion of the tender offers.

(i) For 2025, the Company implemented a phased restructuring initiative aimed at optimizing its legal entity framework. A one-time tax benefit was achieved as part of this restructuring which is partially offset by the execution costs to implement.

(j) For 2025, represents the net impact of costs related to severance, including accelerated stock compensation expense, for certain executives who have separated from the Company.

(k) The income tax effects of non-GAAP adjustments are calculated based on the applicable statutory tax rate for the relevant jurisdiction, except for those items which are non-taxable or subject to valuation allowances for which the tax expense (benefit) was calculated at 0%. The tax benefit for amortization is calculated in a similar manner as the tax effects of the non-GAAP adjustments.

(l) For each of the six months ended June 30, 2026 and June 30, 2025, reported and adjusted net income from continuing operations are each decreased by income attributable to non-controlling interest from continuing operations of $1 million.

(m) Represents all amortization of intangible assets acquired in connection with acquisitions, net of tax.

**International Flavors & Fragrances Inc.**
**Debt Covenants**
**(Amounts in millions)**
**(Unaudited)**

The following information and schedules provide reconciliation information between reported GAAP amounts and non-GAAP certain adjusted amounts. This information and schedules are not intended as, and should not be viewed as, a substitute for reported GAAP amounts or financial statements of the Company prepared and presented in accordance with GAAP.

**Reconciliation of Credit Adjusted EBITDA to Net Income[1]**

| *(DOLLARS IN MILLIONS)* | | **Twelve Months Ended June 30, 2026** |
|---|---|---|
| Net income | $ | 254 |
| Interest expense | | 187 |
| Income taxes | | 98 |
| Depreciation and amortization | | 948 |
| Specified items[2] | | 341 |
| Non-cash items[3] | | 228 |
| **Credit Adjusted EBITDA** | $ | 2,056 |

(1) Credit Adjusted EBITDA presented includes results from continuing and discontinued operations.

(2) Specified items consisted of restructuring and other charges, impairment of goodwill, divestiture costs, strategic initiatives costs, regulatory costs, and other costs that are not related to recurring operations.

(3) Non-cash items consisted of losses (gains) on sale of assets, losses (gains) on business disposals, loss on assets classified as held for sale, and stock-based compensation.

**Reconciliation of Net Debt to Total Debt**

| *(DOLLARS IN MILLIONS)* | | **June 30, 2026** |
|---|---|---|
| Total debt[1] | $ | 5,735 |
| Adjustments: | | |
| Cash and cash equivalents | | 569 |
| **Net debt** | $ | 5,166 |

(1) Total debt used for the calculation of net debt consisted of short-term debt, long-term debt, short-term finance lease obligations and long-term finance lease obligations.

**International Flavors & Fragrances Inc.**
**Comparable Currency Neutral Segment Performance**
**(Amounts in millions)**
**(Unaudited)**

The following information and schedule provides reconciliation information between reported GAAP amounts and non-GAAP certain adjusted amounts. This information and schedule is not intended as, and should not be viewed as, a substitute for reported GAAP amounts or financial statements of the Company prepared and presented in accordance with GAAP.

| | Three Months Ended June 30, | | Six Months Ended June 30, | |
|---|---|---|---|---|
| | 2026 | 2025 | 2026 | 2025 |
| **Net Sales** | | | | |
| Taste[(1)] | $ 679 | $ 650 | $ 1,337 | $ 1,294 |
| Health & Biosciences | 587 | 559 | 1,134 | 1,079 |
| Scent | 650 | 603 | 1,272 | 1,217 |
| Pharma Solutions[(2)] | — | — | — | — |
| Consolidated | $ 1,916 | $ 1,812 | $ 3,743 | $ 3,590 |
| **Segment Adjusted Operating EBITDA[(5)]** | | | | |
| Taste[(1)] | $ 122 | $ 115 | $ 268 | $ 236 |
| Health & Biosciences | 146 | 138 | 277 | 256 |
| Scent | 126 | 120 | 258 | 253 |
| Pharma Solutions[(2)] | — | — | — | — |
| Total | 394 | 373 | 803 | 745 |
| Depreciation & Amortization | (154) | (146) | (306) | (288) |
| Interest Expense | (46) | (61) | (90) | (132) |
| Other Expense, net | (20) | (20) | (33) | (39) |
| Restructuring and Other Charges | (6) | (20) | (10) | (35) |
| Impairment of Goodwill | — | — | — | (34) |
| Losses on Business Disposals | (1) | (111) | (1) | (111) |
| Loss on Assets Classified as Held for Sale | (27) | — | (27) | — |
| Divestiture Costs | (10) | (26) | (15) | (77) |
| Strategic Initiative Costs | (9) | (6) | (18) | (14) |
| Regulatory Costs | (71) | (53) | (81) | (64) |
| Gain on Debt Extinguishment | — | 488 | — | 488 |
| Entity Realignment Costs | (1) | (4) | (2) | (5) |
| Other | 1 | (2) | 2 | (6) |
| Impact of Currency Fluctuations[(3)] | 14 | — | 38 | — |
| Impact of Business Divestitures[(4)] | — | 26 | — | 98 |
| Income from continuing operations before taxes | $ 64 | $ 438 | $ 260 | $ 526 |
| **Segment Adjusted Operating EBITDA Margin[(4)]** | | | | |
| Taste | 18.0 % | 17.7 % | 20.0 % | 18.2 % |
| Health & Biosciences | 24.9 % | 24.7 % | 24.4 % | 23.7 % |
| Scent | 19.4 % | 19.9 % | 20.3 % | 20.8 % |
| Consolidated | 20.6 % | 20.6 % | 21.5 % | 20.8 % |

(1) Taste sales and segment adjusted operating EBITDA information exclude the results of the Rene Laurent business that was divested on December 1, 2025, to present fully comparable scenarios.

(2) Pharma sales and segment adjusted operating EBITDA information exclude the results of the Pharma Solutions disposal group and Nitrocellulose business that were divested on May 1, 2025 and May 9, 2025, respectively, to present fully comparable scenarios.

(3) Currency neutral sales are calculated by translating current year invoiced sale amounts at the exchange rates for the corresponding prior year period.

(4) Amounts exclude the results of the Rene Laurent business that was divested on December 1, 2025 and the Pharma Solutions disposal group and Nitrocellulose business that were divested on May 1, 2025 and May 9, 2025, respectively, to present fully comparable scenarios.

(5) Following the completed divestitures of the Pharma Solutions disposal group on May 1, 2025 and the Nitrocellulose business on May 9, 2025, the Company reallocated certain corporate costs previously attributed to the Pharma Solutions segment. These costs have been redistributed across the Taste, Health & Biosciences, and Scent segments to align with the updated 2025 operating model.

| | **Three Months Ended June 30, 2025** | |
|---|---|---|
| | Selling & Administrative Expenses | Total EBITDA Impact |
| Taste | $ 1 | $ (1) |
| Health & Biosciences | 1 | (1) |
| Scent | 1 | (1) |
| Total | $ 3 | $ (3) |

| | **Six Months Ended June 30, 2025** | |
|---|---|---|
| | Selling & Administrative Expenses | Total EBITDA Impact |
| Taste | $ 6 | $ (6) |
| Health & Biosciences | 6 | (6) |
| Scent | 6 | (6) |
| Total | $ 18 | $ (18) |

**International Flavors & Fragrances Inc.**
**GAAP to Non-GAAP Reconciliation**
**Comparable Foreign Exchange Impact**
**(Unaudited)**

| Q2 Taste | Sales | Segment Adjusted Operating EBITDA | Segment Adjusted Operating EBITDA Margin |
|---|---|---|---|
| **% Change - Reported** | 5% | 6% | 0.1% |
| Portfolio Impact | 1% | 2% | 0.2% |
| **% Change - Comparable** | 6% | 8% | 0.3% |
| Currency Impact | (2)% | (2)% | 0.0% |
| **% Change - Currency Neutral** | 4% | 6% | 0.3% |

| Q2 Health & Biosciences | Sales | Segment Adjusted Operating EBITDA | Segment Adjusted Operating EBITDA Margin |
|---|---|---|---|
| **% Change - Reported** | 8% | 8% | 0.1% |
| Portfolio Impact | 0% | 1% | 0.2% |
| **% Change - Comparable** | 8% | 9% | 0.3% |
| Currency Impact | (3)% | (3)% | (0.1)% |
| **% Change - Currency Neutral** | 5% | 6% | 0.2% |

| Q2 Scent | Sales | Segment Adjusted Operating EBITDA | Segment Adjusted Operating EBITDA Margin |
|---|---|---|---|
| **% Change - Reported** | 10% | 11% | 0.1% |
| Portfolio Impact | 0% | 1% | 0.1% |
| **% Change - Comparable** | 10% | 12% | 0.2% |
| Currency Impact | (2)% | (7)% | (0.7)% |
| **% Change - Currency Neutral** | 8% | 5% | (0.5)% |

| Q2 Consolidated | Sales | Adjusted Operating EBITDA | Adjusted Operating EBITDA Margin |
|---|---|---|---|
| **% Change - Reported** | 2% | 2% | 0.1% |
| Portfolio Impact | 6% | 7% | 0.2% |
| **% Change - Comparable** | 8% | 9% | 0.3% |
| Currency Impact | (2)% | (3)% | (0.3)% |
| **% Change - Currency Neutral** | 6% | 6% | 0.0% |

Note: The sum of these items may not foot due to rounding.

**International Flavors & Fragrances Inc.**
**GAAP to Non-GAAP Reconciliation**
**Comparable Foreign Exchange Impact**
**(Unaudited)**

| YTD Taste | Sales | Segment Adjusted Operating EBITDA | Segment Adjusted Operating EBITDA Margin |
|---|---|---|---|
| **% Change - Reported** | 5% | 12% | 1.3% |
| Portfolio Impact | 1% | 5% | 0.6% |
| **% Change - Comparable** | 6% | 17% | 1.9% |
| Currency Impact | (3)% | (3)% | (0.1)% |
| **% Change - Currency Neutral** | 3% | 14% | 1.8% |

| YTD Health & Biosciences | Sales | Segment Adjusted Operating EBITDA | Segment Adjusted Operating EBITDA Margin |
|---|---|---|---|
| **% Change - Reported** | 9% | 11% | 0.4% |
| Portfolio Impact | 0% | 2% | 0.4% |
| **% Change - Comparable** | 9% | 13% | 0.8% |
| Currency Impact | (4)% | (5)% | (0.2)% |
| **% Change - Currency Neutral** | 5% | 8% | 0.6% |

| YTD Scent | Sales | Segment Adjusted Operating EBITDA | Segment Adjusted Operating EBITDA Margin |
|---|---|---|---|
| **% Change - Reported** | 8% | 6% | (0.4)% |
| Portfolio Impact | 0% | 3% | 0.6% |
| **% Change - Comparable** | 8% | 9% | 0.2% |
| Currency Impact | (3)% | (7)% | (0.7)% |
| **% Change - Currency Neutral** | 5% | 2% | (0.5)% |

| YTD Consolidated | Sales | Adjusted Operating EBITDA | Adjusted Operating EBITDA Margin |
|---|---|---|---|
| **% Change - Reported** | (3)% | 0% | 0.6% |
| Portfolio Impact | 11% | 13% | 0.4% |
| **% Change - Comparable** | 8% | 13% | 1.0% |
| Currency Impact | (4)% | (5)% | (0.3)% |
| **% Change - Currency Neutral** | 4% | 8% | 0.7% |

Note: The sum of these items may not foot due to rounding.